keyword
MENU ▼
Read by QxMD icon Read
search

dalteparin

keyword
https://www.readbyqxmd.com/read/27850475/837-comparative-effectiveness-of-enoxaparin-vs-dalteparin-for-thromboprophylaxis-after-traumatic-injury
#1
Todd Miano, Niels Martin, Adam Cuker, Brian Smith, Jason Christie, Wensheng Guo, Sean Hennessy
No abstract text is available yet for this article.
December 2016: Critical Care Medicine
https://www.readbyqxmd.com/read/27811198/the-efficacy-and-safety-of-edoxaban-for-vte-prophylaxis-post-orthopedic-surgery-a-systematic-review
#2
Lamia AlHajri, Sima Jabbari, Hind AlEmad, Khawla AlMahri, Maryam AlMahri, Noora AlKitbi
BACKGROUND: Venous thromboembolism (VTE) is a common complication that manifests during and/or after hospitalization, as well as postsurgeries including orthopedic surgeries. Edoxaban is a new oral direct factor Xa inhibitor that has been recently approved for treating VTE in patients who have already been treated with a parenteral anticoagulant and for the prevention of stroke and non-central nervous system systemic embolism in patients with nonvalvular atrial fibrillation. OBJECTIVES: The purpose of this systematic review was to evaluate the safety and efficacy of edoxaban for VTE prophylaxis after lower limb orthopedic surgery...
November 2, 2016: Journal of Cardiovascular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27737872/dalteparin-sodium-induced-drug-fever-in-a-neonate
#3
Dirk Wackernagel, Sami Obaya, Per Nydert
Drug fever caused by dalteparin-sodium (DS), a low-molecular-weight derivative of heparin, is neither listed in the official drug information and nor published as a case report until today. A preterm infant, born at 26 weeks of gestation, developed fever 2 days after starting a treatment with DS for an intracardial thrombus. The fever reverses soon after changing the treatment to unfractionated heparin and reappeared after reintroduction of DS. Once again, after discontinuing DS, the infant regained normothermia...
October 13, 2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27720420/perioperative-thromboprophylaxis-in-severely-obese-patients-undergoing-bariatric-surgery-insights-from-a-french-national-survey
#4
Pierre-Antoine Moulin, Anne Dutour, Patricia Ancel, Pierre-Emmanuel Morange, Thierry Bege, Olivier Ziegler, Stéphane Berdah, Corinne Frère, Bénédicte Gaborit
BACKGROUND: Venous thromboembolism (VTE) is a leading cause of death in obese patients undergoing bariatric surgery (BS), but there is neither consensus nor high-level guidelines yet on VTE prophylaxis in this specific population. OBJECTIVE: We aimed to evaluate patterns of BS perioperative thromboprophylaxis practices. SETTING: French obesity specialized care centers (CSO), which are tertiary care referral hospitals for the most severe cases of obesity METHODS: A detailed questionnaire survey (11 opened, 15 closed questions) investigating their prophylactic schemes of anticoagulation (molecule, dose, weight-adjustment, duration, associated measures, follow-up) was sent to the 37 CSO...
September 1, 2016: Surgery for Obesity and related Diseases: Official Journal of the American Society for Bariatric Surgery
https://www.readbyqxmd.com/read/27717636/the-effect-of-dalteparin-on-thromboelastography-in-pregnancy-an-in-vitro-study
#5
L Chow, A Carr, L MacKenzie, A Walker, D Archer, A Lee
BACKGROUND: Dalteparin is often used for prophylaxis or treatment of venous thromboembolism during pregnancy, yet there is no laboratory test to accurately reflect its clinical activity. Thromboelastography is a point-of-care monitor of whole blood coagulation. The aim of this study was to determine if serial doses of dalteparin added in vitro to whole blood samples from term, pregnant women are detectable as changes in thromboelastography parameters. METHODS: Thirty healthy parturients presenting for elective caesarean section were recruited...
December 2016: International Journal of Obstetric Anesthesia
https://www.readbyqxmd.com/read/27712038/evaluation-of-an-oral-direct-factor-xa-inhibitor-anticoagulant-in-healthy-adult-horses
#6
Maria L Rodríguez-Pozo, Lara Armengou, Luis Monreal, Judit Viu, Carla Cesarini, Eduard Jose-Cunilleras
OBJECTIVE: To assess whether an oral direct factor Xa inhibitor (DiXaI) anticoagulant drug used at the low end of the recommended dose in people achieves presumed prophylactic plasma concentrations and does not induce bleeding in horses. DESIGN: Experimental study. SETTING: Field study. ANIMALS: Ten healthy adult horses. INTERVENTIONS: A DiXaI was administered at a dose of 0.125 mg/kg every 24 h orally for 4 days...
October 6, 2016: Journal of Veterinary Emergency and Critical Care
https://www.readbyqxmd.com/read/27658532/postoperative-start-compared-to-preoperative-start-of-low-molecular-weight-heparin-increases-mortality-in-patients-with-femoral-neck-fractures
#7
Sunniva Leer-Salvesen, Eva Dybvik, Ola E Dahl, Jan-Erik Gjertsen, Lars B EngesæTer
Background and purpose - Controversies exist regarding thromboprophylaxis in orthopedic surgery. Using data in the nationwide Norwegian Hip Fracture Register (NHFR) with postoperative death and reoperation in the first 6 months after surgery as endpoints in the analyses, we determined whether the thromboprophylaxis in patients who undergo hemiarthroplasty for femoral neck fracture should start preoperatively or postoperatively. Patients and methods - After each operation for hip fracture in Norway, the surgeon reports information on the patient, the fracture, and the operation to the NHFR...
September 23, 2016: Acta Orthopaedica
https://www.readbyqxmd.com/read/27543162/venous-thromboembolism-treatment-outcomes-in-cancer-patients-and-effect-of-third-party-payers-on-anticoagulant-choice
#8
Gary W Jean, Katherine Kelly, Jennie Mathew, Eneko Larumbe, Randall Hughes
PURPOSE: The purpose of this study is to compare the rates of recurrent VTE among cancer patients treated with parenteral agents to the oral anticoagulants. METHODS: This single-center study was a retrospective chart review of cancer patients with recurrent VTE between January 1, 2009 and December 31, 2014. The primary outcome of the study is the rate of recurrent VTE in patients who received a parenteral anticoagulant (enoxaparin, dalteparin, fondaparinux) versus those who received oral anticoagulants (warfarin and rivaroxaban)...
January 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27441664/compatibility-of-injectable-anticoagulant-agents-in-ethanol-in-vitro-antibiofilm-activity-and-impact-on-polyurethane-catheters-of-enoxaparin-400-u-ml-in-40-v-v-ethanol
#9
Damien Balestrino, Mercédès Quintana, Nicolas Charbonnel, Christiane Forestier, Claire Lartigue, Bertrand Souweine
BACKGROUND AND OBJECTIVES: Interdialytic lock solutions should maintain catheter patency and prevent catheter infections. We aimed to determine in which conditions injectable anticoagulant agents (IAAs) combined with ethanol are compatible and to assess the antibiofilm activity of the selected combination and its effects on dialysis catheters (DC). METHODS: The solubility and compatibility of unfractionated heparin (UFH), low molecular weight heparins (LMWHs), heparinoids and fondaparinux (50 to 2,500 U/mL) in 30 to 70% ethanol were determined by visual observation...
2016: PloS One
https://www.readbyqxmd.com/read/27440387/lmwh-in-the-prevention-of-preeclampsia-and-fetal-growth-restriction-in-women-without-thrombophilia-a-systematic-review-and-meta-analysis
#10
Salvatore Andrea Mastrolia, Lena Novack, Jecko Thachil, Anat Rabinovich, Oleg Pikovsky, Vered Klaitman, Giuseppe Loverro, Offer Erez
Placental mediated pregnancy complications such as preeclampsia and fetal growth restriction (FGR) are common, serious, and associated with increased morbidity and mortality. We conducted a systematic review and meta-analysis to determine the effect of treatment with low-molecular-weight heparins (LMWHs) for secondary prevention of these complications in non thrombophilic women. We searched the electronic databases PubMed, Scopus, and Cochrane Library for randomised controlled trials addressing this question...
July 21, 2016: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/27436663/economic-analysis-comparing-dalteparin-to-vitamin-k-antagonists-to-prevent-recurrent-venous-thromboembolism-in-patients-with-cancer-having-renal-impairment
#11
George Dranitsaris, Lesley Shane, Laura Burgers, Seth Woodruff
BACKGROUND: In a randomized trial (ie, Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer [CLOT]) that evaluated secondary prophylaxis of recurrent venous thromboembolism (VTE) in patients with cancer, dalteparin reduced the relative risk by 52% compared to oral vitamin K antagonists (VKAs; hazard ratio = 0.48, P = .002). A recent subgroup analysis in patients with moderate to severe renal impairment also revealed lower absolute VTE rates with dalteparin (3% vs 17%; P = ...
October 2016: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/27347822/assessment-of-the-effects-of-dalteparin-on-coagulation-variables-and-determination-of-a-treatment-schedule-for-use-in-cats
#12
Jette C Schönig, Reinhard H Mischke
OBJECTIVE To determine a treatment protocol for SC administration of dalteparin to cats on the basis of currently available detailed pharmacokinetic data and to assess the effect of SC administration of dalteparin to cats on coagulation variables such as activated partial thromboplastin time (aPTT), thrombin time, and results for thromboelastometry, compared with effects on anti-activated coagulation factor X (anti-Xa) activity. ANIMALS 6 healthy domestic shorthair cats. PROCEDURES Cats received 14 injections of dalteparin (75 anti-Xa U/kg, SC) at 6-hour intervals...
July 2016: American Journal of Veterinary Research
https://www.readbyqxmd.com/read/27344439/a-post-hoc-analysis-of-dalteparin-versus-oral-anticoagulant-vka-therapy-for-the-prevention-of-recurrent-venous-thromboembolism-rvte-in-patients-with-cancer-and-renal-impairment
#13
Seth Woodruff, Guillaume Feugère, Paula Abreu, Joseph Heissler, Marcia T Ruiz, Frank Jen
Venous thromboembolism (VTE) is a common and serious complication in patients with cancer; treatment guidelines recommend extended therapy of ≥6 months with low-molecular-weight heparin (LMWH) for treatment and prevention of recurrent VTE (rVTE) in this population. This post hoc analysis used data from the CLOT study-a phase III, randomized, open-label, controlled study (N = 676)-to compare the efficacy and safety of dalteparin, a LMWH, versus vitamin K antagonist (VKA) for prevention of rVTE in patients with cancer and renal impairment (creatinine clearance <60 ml/min)...
November 2016: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/27301751/blocking-inhibition-of-prothrombinase-by-tissue-factor-pathway-inhibitor-alpha-a-procoagulant-property-of-heparins
#14
Jeremy P Wood, Lisa M Baumann Kreuziger, Umesh R Desai, Alan E Mast
Unfractionated heparin (UFH) has procoagulant activity in antithrombin/heparin cofactor II (HCII)-depleted plasma. UFH prevents tissue factor pathway inhibitor alpha (TFPIα) from inhibiting the procoagulant enzyme complex, prothrombinase, providing a possible mechanism for its procoagulant activity. The procoagulant potential of UFH and various low molecular weight heparins (LMWHs) were characterized for TFPIα dependence, using thrombin generation assays performed with antithrombin/HCII-depleted plasma. UFH, the LMWHs enoxaparin and dalteparin, and the low anticoagulant LMWH 2-O, 3-O desulphated heparin (ODSH) all promoted thrombin generation, but fondaparinux did not, and this activity was blocked by a TFPIα antibody...
October 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27274299/enhanced-effect-of-fibroblast-growth-factor-2-containing-dalteparin-protamine-nanoparticles-on-hair-growth
#15
Yuki Takabayashi, Masaki Nambu, Masayuki Ishihara, Masahiro Kuwabara, Koichi Fukuda, Shingo Nakamura, Hidemi Hattori, Tomoharu Kiyosawa
PURPOSE: Although treatments for alopecia are in high demand, not all treatments are safe and reliable. Dalteparin/protamine nanoparticles (D/P NPs) can effectively carry growth factors (GFs) such as fibroblast GF (FGF)-2. The purpose of this study was to identify the effects of FGF-2-containing D/P NPs (FGF-2&D/P NPs) on hair growth. PATIENTS AND METHODS: In this study, the participants were 12 volunteers with thin hair. One milliliter of FGF-2 (100 ng/mL) and D/P NPs (56 μg/mL) was applied and massaged on the skin of the scalp by the participants twice a day...
2016: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/27236710/prolonged-low-molecular-weight-heparin-use-during-pregnancy-and-subsequent-bone-mineral-density
#16
Päivi Galambosi, Vilho Hiilesmaa, Veli-Matti Ulander, Leena Laitinen, Aila Tiitinen, Risto Kaaja
INTRODUCTION: In contrast to unfractionated heparin (UFH), use of low-molecular weight heparin (LMWH) during pregnancy has not been reported to be associated with a significant decrease in bone mineral density (BMD). The aim of this study was to investigate whether long-term use of LMWH during pregnancy is associated with subsequent decrease in BMD or with increased number of osteoporotic fractures. MATERIALS AND METHODS: In this observational cohort study BMD was measured by dual energy X-ray absorptiometry (DEXA) 4-7years after the last delivery in 152 women...
July 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27162925/incidence-of-deep-vein-thrombosis-in-patients-undergoing-degenerative-spine-surgery-onprophylactic-dalteparin-a-single-center-report
#17
AlirezaFarid Moayer, Navideh Mohebali, Ali Razmkon
OBJECTIVE: To determine the incidence of deep vein thrombosis (DVT)in patients undergoing spinal surgeries receiving prophylactic doses of Deltaparin in a single center in central Iran. METHOD: This cross-sectional study was conducted in Shariatee hospital of Isfahan during a 12-month period. We included all the patients undergoing elective spinal surgeries in our center during the study period who received prophylactic dosages of subcutaneous Dalteparin (5000unit daily) thefirst postoperative day...
January 2016: Bulletin of Emergency and Trauma
https://www.readbyqxmd.com/read/27161727/po-39-primary-thromboprophylaxis-for-ambulatory-patients-with-advanced-metastatic-pancreatic-cancer-a-practical-implementation-of-lessons-from-published-experience
#18
G Bozas, I A Muazzam, W Ilyas, A Maraveyas
INTRODUCTION: The efficacy and safety of primary prophylaxis in advanced pancreatic cancer (APC) has been demonstrated in randomized controlled studies. Current guidelines suggest use of primary prophylaxis in high risk ambulatory cancer patients. The VTE in cancer working group in our centre reviewed our experience with FRAGEM and relevant literature. OBSERVATIONS: (1) Dose: (a) conventional prophylactic dosing is not established in APC (b) 200IU/kg followed by 150IU/kg dalteparin may be superior to 1mg/kg followed by 40mg enoxaparin...
April 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27161683/oc-11-anticoagulation-therapy-in-selected-cancer-patients-at-risk-of-recurrence-of-venous-thromboembolism
#19
A Young, J Phillips, H Hancocks, C Hill, N Joshi, A Marshall, J Grumett, J A Dunn, A Lokare, O Chapman
INTRODUCTION: Venous thromboembolism (VTE) in cancer patients is an increasingly frequent clinical problem. The overall impact of VTE on cancer patients can be considerable. Targeted patient selection by identifying patients with clinically significant recurrent VTE may have wider health economic benefits whilst reducing patient risk through over-treatment. In the UK, dalteparin is one licensed anticoagulant for the extended treatment and prevention of recurrence of VTE in cancer patients...
April 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27110105/weight-based-dosing-in-medication-use-what-should-we-know
#20
REVIEW
Sheng-Dong Pan, Ling-Ling Zhu, Meng Chen, Ping Xia, Quan Zhou
BACKGROUND: Weight-based dosing strategy is still challenging due to poor awareness and adherence. It is necessary to let clinicians know of the latest developments in this respect and the correct circumstances in which weight-based dosing is of clinical relevance. METHODS: A literature search was conducted using PubMed. RESULTS: Clinical indications, physiological factors, and types of medication may determine the applicability of weight-based dosing...
2016: Patient Preference and Adherence
keyword
keyword
50342
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"